THERAPEUTIC EFFICIENCY OF RANIBIZUMAB AND 4-METHYL CATECHOL ON THE PROGRESSION OF STREPTOZOTOCIN-INDUCED DIABETIC RETINOPATHY IN RATS: INVOLVING VASCULAR ENDOTHELIAL GROWTH FACTOR-A AND NERVE GROWTH FACTOR | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Article 41, Volume 47, Issue 1, June 2024, Pages 613-627 PDF (1.69 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfsa.2023.244738.1956 | ||
| Authors | ||
| Eman Elsayed* 1; Amira El-Saadany1; Walaa Elwan2; Amany Abdin1; Fleur Abd Elmonem1 | ||
| 1Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt | ||
| 2Histology Department, Faculty of Medicine, Tanta University, Egypt | ||
| Abstract | ||
| Purpose: Diabetic retinopathy (DR) is a chronic microvascular diabetic complication leading to visual loss. Ranibizumab (RBZ) is a monoclonal antibody inhibiting VEGF-A, approved for DR treatment. 4-Methyl catechol (4MC) is a potent NGF stimulant & possesses a neuroprotective effect in neuronal diseases. The aim of this study was to evaluate the role of 4MC in comparison to RBZ in the progression of streptozotocin (STZ) induced-diabetic retinopathy in albino rats. Methods: This experiment was performed on 40 albino rats divided equally into: (normal control, untreated DR, RBZ treated intravitreally & 4MC treated intravitreally). Results: The untreated DR group revealed a significant elevation of fasting serum glucose, VEGF-A, histopathological score & IHC score of Tie-2, and a significant decrease in NGF, and IHC of Bcl-2 versus the normal control group. Treatment with either RBZ or 4MC produced significant improvement in the forementioned parameters when compared to the untreated DR group. Conclusion: RBZ and 4MC are effective in the progression of STZ-induced DR via inhibition of VEGF-A and stimulation of NGF respectively. | ||
| Keywords | ||
| Diabetic retinopathy; Streptozotocin; Ranibizumab; 4-Methyl catechol | ||
|
Statistics Article View: 278 PDF Download: 316 |
||
